Melatonin Research Says 0.3mg. Your Bottle Says 10mg. Someone Is Wrong.
Three decades of clinical research established the effective dose of melatonin for sleep. The supplement industry arrived at a very different number. Here's what the evidence actually shows — including why most melatonin users are taking 10 to 30 times more than studies support.
In this article9 sections
Walk into any American pharmacy and the melatonin shelf will offer you 3mg, 5mg, 10mg — sometimes 20mg — tablets, gummies, and dissolving strips. The labels describe a product that promotes restful sleep and helps with occasional sleeplessness. What they will not tell you is that the dose in the average commercial product is somewhere between 6 and 30 times higher than what decades of clinical research found effective.
Direct answer: Physiologically effective melatonin doses for shifting sleep timing range from 0.1mg to 0.5mg, based on research dating to Dr. Richard Wurtman’s foundational 1994 work at MIT. The 10mg tablet most Americans take is not more effective than 0.3mg — it stays in the bloodstream longer, which is why it causes next-morning grogginess that users typically misattribute to poor sleep rather than their supplement dose.
What Melatonin Is — and Isn’t
The most common misconception about melatonin is categorical: it’s treated as a sleeping pill, which it isn’t.
Melatonin is a chronobiotic — a compound that influences the timing of the body’s internal clock rather than inducing sedation. A benzodiazepine or diphenhydramine (the antihistamine in most OTC sleep aids) produces drowsiness through direct action on GABA or histamine receptors. You get sedated because the compound is actively suppressing arousal.
Melatonin doesn’t work this way. It’s a hormonal signal produced by the pineal gland in response to darkness, and its primary role is communicating “it is dark outside” to the body’s biological systems. It begins rising about two hours before natural sleep onset, peaks in the middle of the night, and falls as light returns. What it does, functionally, is shift the internal clock — not knock you out.
Understanding this mechanism explains why timing matters more than dose.
How the Research Established 0.3mg
Dr. Richard Wurtman, a neuroendocrinologist at the Massachusetts Institute of Technology, began studying melatonin’s physiological role in the early 1990s. His 1994 paper in Neuroendocrinology Letters established that doses between 0.1mg and 0.3mg were sufficient to raise blood melatonin levels to concentrations found during natural nighttime production in young healthy adults — roughly 100 to 200 picograms per milliliter.
His key finding: doses above this threshold did not produce proportionally stronger sleep effects. What they produced was a longer-duration melatonin elevation — blood levels that peaked higher and remained elevated for more hours. A 10mg dose doesn’t work ten times better than 0.3mg at shifting sleep timing. It works approximately the same, but it lingers until mid-morning instead of clearing by early morning.
Wurtman’s dose-response studies compared 0.3mg to 1mg, 3mg, and 10mg in healthy subjects. At 0.3mg, morning alertness was normal. At 3mg and above, subjects reported significant next-morning sedation. These findings were replicated across multiple studies through the late 1990s and 2000s.
Dr. Josephine Arendt at the University of Surrey, whose circadian and melatonin research spans more than four decades and includes foundational jet lag work, published consistent findings: low doses (0.5mg) administered at the right time were as effective as higher doses for circadian phase shifting, with substantially fewer next-day effects.
Why Your Bottle Says 10mg
The United States is an outlier in melatonin regulation, and understanding why explains the commercial dosing problem directly.
In 1994 — the same year Wurtman published his dose-response findings — the US Congress passed the Dietary Supplement Health and Education Act. DSHEA classified supplements, including melatonin, as foods rather than drugs, removing the requirement for pre-market efficacy or safety testing. Manufacturers can sell melatonin in any dose without demonstrating clinical effectiveness at that dose.
In Canada, the UK, and across the European Union, melatonin is regulated as a pharmaceutical. In the UK, doses above 0.5mg require a physician’s prescription. The EU permits over-the-counter sales at 0.5–1mg for specific indications, primarily jet lag. A Canadian resident cannot walk into a pharmacy and buy a 10mg tablet; an American can walk in and choose from twelve brands offering doses up to 20mg.
The dosing discrepancy exists not because the science points to different conclusions in different countries. It exists because US regulatory framework allows manufacturers to decide what dose they sell — and in a market where consumers associate dose with potency, there is commercial incentive to make the tablet bigger.
The Manufacturing Quality Problem
The dose problem is compounded by a manufacturing problem documented in a 2017 analysis published in the Journal of Clinical Sleep Medicine by Lauren Erland and Praveen Saxena at the University of Guelph.
Erland and Saxena tested 31 commercial melatonin products — tablets, gummies, and liquids — for actual melatonin content versus the label claim:
- Actual content ranged from 17% to 478% of the stated dose
- 71% of products had actual content more than 10% different from the label
- 26% of products contained serotonin — a controlled precursor not listed on the label
The product labeled “0.5mg” might contain 2.4mg. The 10mg tablet might contain 47.8mg. If you’re trying to take the low, effective dose and you buy a product with 400% overages, you’re taking the high dose by accident.
Melatonin and Age: A Different Dosing Conversation
The dose question is further complicated by age-related changes in melatonin production. Natural melatonin levels decline significantly with age — estimates suggest adults over 60 produce roughly 50% less melatonin than adults in their twenties.
Dr. Irina Zhdanova, who conducted extensive dose-response research at MIT in the 1990s and early 2000s, published findings suggesting that older adults with low baseline melatonin levels showed more pronounced sleep improvements from low-dose supplementation than younger subjects with normal baseline production.
The implication: if melatonin supplementation has a target population with the strongest evidence base, it may be adults over 55 experiencing age-related sleep changes — not the 32-year-old who’s been eating 10mg gummies at 10 PM for six months.
For children, the picture is different and the uncertainty is greater. Pediatric melatonin use in the US grew substantially over the past decade — the CDC’s National Health Interview Survey found 1.3% of American children under 18 were taking melatonin in 2018, up from near zero in 2006. The evidence base for this use is thin, and most pediatric sleep specialists recommend addressing behavioral contributors before supplementation. The long-term effects of melatonin on developing endocrine systems are not well understood. This is an area where the honest answer is genuine uncertainty.
Timing: The Variable Most Users Ignore
Melatonin’s clock-shifting effect is largest when taken 2–3 hours before desired sleep onset. This finding appears consistently across jet lag studies, delayed sleep phase research, and experimental phase-shifting protocols.
Lewy, Ahmed, Jackson, and Sack (1998) in Chronobiology International showed that melatonin taken in the early evening — roughly 1.5–3 hours before target bedtime — produced phase advances comparable to light therapy, while the same dose taken at bedtime produced smaller phase advances and more next-day sedation.
Most users take melatonin at bedtime, which is exactly when the pineal gland has already begun natural production. Supplemental melatonin stacks on endogenous production, creating the blood level peak that produces morning grogginess.
A dose-timing reference based on available research:
| Use Case | Recommended Dose | Recommended Timing |
|---|---|---|
| Jet lag — westward travel | 0.5mg | At destination bedtime, 3 nights |
| Jet lag — eastward travel | 0.3–0.5mg | 2–3 hours before target sleep, 3 nights |
| Schedule shift (sleeping earlier) | 0.3–0.5mg | 2 hours before target bedtime |
| Occasional difficulty falling asleep | 0.5mg | 60–90 minutes before bed |
| Typical US commercial approach | 5–10mg | At bedtime |
The last row describes what most American users actually do. It is the pattern most inconsistent with how the hormone operates.
What Higher Doses Actually Do
Studies measuring effects of doses above 1mg find a consistent set of outcomes beyond the desired timing shift:
-
Extended blood presence. Melatonin’s half-life is approximately 45 minutes at low doses. At high doses, blood levels remain meaningful for 6–8 hours after administration.
-
Next-morning sedation. Zhdanova et al. (1995, 1997) at MIT measured decreases in morning alertness at doses of 1mg and above that were not present at 0.3mg.
-
Potential endogenous modulation. There is debated evidence that chronic high-dose supplementation may modulate the body’s own melatonin production downward through feedback inhibition. The evidence in humans is limited to short-term studies. Caution is warranted for long-term daily high-dose use; evidence for harm at low doses is not established.
Honest Limitations
The research supporting low-dose effectiveness is robust for specific populations: jet-lagged individuals, people with delayed sleep phase disorder, and healthy adults experimentally phase-shifting their schedules. Extrapolating to everyone who takes melatonin for general sleeplessness requires a step the research hasn’t fully validated.
Individual variation in melatonin metabolism is real. The CYP1A2 enzyme that breaks down melatonin shows significant genetic variation across populations. Coffee, oral contraceptives, and certain antibiotics inhibit it, effectively raising blood melatonin levels for a given dose. “The right dose” is not the same number for everyone.
I’m also aware that recommending 0.3mg is somewhat academic when most 0.3mg products are hard to find and the manufacturing variance Erland and Saxena documented makes label accuracy uncertain. The practical recommendation is to start at the lowest commercially available dose and assess effects — which is itself imprecise.
Three Changes Worth Making
Cut the dose. If you’re currently taking 5mg or 10mg, find a 0.5mg product and trial it for two weeks. Most people find their sleep onset unaffected and their mornings meaningfully clearer.
Move the dose earlier. If your target bedtime is 10:30 PM and you’re taking melatonin at 10:20 PM, shift the dose to 8:30 PM. This sounds counterintuitive — taking a sleep supplement two hours before bed. It’s how the biology works.
Use it for transitions, not indefinitely. Jet lag, schedule reset after travel or illness, deliberate phase advancement: these are the use cases where the evidence base is strongest. As a nightly indefinite supplement, the evidence for sustained benefit is weaker than the product marketing implies.
DontSnooze (dontsnooze.io) doesn’t prescribe anything and can’t fix your dose. What it addresses is the behavioral half of a sleep schedule problem — the part where the alarm fires and the commitment dissolves. Worth saying plainly: most people who struggle with sleep schedules have a behavioral problem wearing a biochemical costume. The melatonin research is genuinely fascinating. For most people, it matters less than making the decision to keep the same wake time tomorrow and having a real consequence for not doing it.
Related: